Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

Rovellini, A.; Sommariva, D.; Branchi, Adriana; Maraffi, F; Montalto, Claudio; Gandini, R; Fasoli, A

doi:10.1016/s1043-6618(05)80072-6

Cited by 13 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPAR-primarily regulates gene expression involved in lipid metabolism stimulating increases in high-density lipoprotein and lowering serum triglyceride levels [53]. Bezafibrate was found to reduce triglycerides and significantly decrease fasting plasma glucose levels in type 2 diabetic patients with hyperlipidemia [54]. The glucose-lowering potential of bezafibrate is attributed to its nonselective activation of PPAR, where the subtype is activated in addition to and .…”

Section: Fibric Acid Derivatives (Bezafibrate)mentioning

confidence: 99%

Prevention of type 2 diabetes: An update

Farag

Karam²,

Nicasio³

et al. 2007

Curr Diab Rep

View full text Add to dashboard Cite

With the rising tide of the diabetes epidemic leading to increased morbidity and mortality (primarily from cardiovascular disease), together with failure to control the disease and its associated complications, prevention of diabetes appears to be the logical option for curbing this epidemic. Several trials have been completed, and others ongoing, using various strategies for diabetes prevention. In this review, we provide an update on diabetes prevention strategies, highlighting the rationale behind such interventions, together with an outlook of the ongoing efforts that are likely to provide additional options for patients at risk for diabetes.

show abstract

Section: Fibric Acid Derivatives (Bezafibrate)mentioning

confidence: 99%

Prevention of type 2 diabetes: An update

Farag

Karam²,

Nicasio³

et al. 2007

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…Fibric acids increase HDL-C partly by increasing apolipoprotein A-I and apolipoprotein A-II gene expression. Their triglyceride-lowering and HDL-C raising effects lead to decreased systemic availability of fatty acid, diminished fatty acid uptake by muscle with improvement of insulin sensitization and reduced plasma glucose level [ 36 - 39 ].…”

Section: Reviewmentioning

confidence: 99%

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Tenenbaum

Fisman

Motro

et al. 2006

Cardiovasc Diabetol

View full text Add to dashboard Cite

Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant number of coronary events still occur and many of such events take place in patients presenting with type 2 diabetes and metabolic syndrome. More and more attention is being paid now to combined atherogenic dyslipidemia which typically presents in patients with type 2 diabetes and metabolic syndrome. This mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B) -emerged as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease. Most recent extensions of the fibrates trials (BIP -Bezafibrate Infarction Prevention study, HHS -Helsinki Heart Study, VAHIT -Veterans Affairs High-density lipoprotein cholesterol Intervention Trial and FIELD -Fenofibrate Intervention and Event Lowering in Diabetes) give further support to the hypothesis that patients with insulin-resistant syndromes such as diabetes and/or metabolic syndrome might be the ones to derive the most benefit from therapy with fibrates. However, different fibrates may have a somewhat different spectrum of effects. Other lipid-modifying strategies included using of niacin, ezetimibe, bile acid sequestrants and cholesteryl ester transfer protein inhibition. In addition, bezafibrate as pan-peroxisome proliferator activated receptor activator has clearly demonstrated beneficial pleiotropic effects related to glucose metabolism and insulin sensitivity. Because fibrates, niacin, ezetimibe and statins each regulate serum lipids by different mechanisms, combination therapy -selected on the basis of their safety and effectiveness -may offer particularly desirable benefits in patients with combined hyperlipidemia as compared with statins monotherapy.

show abstract

“…18 -21 In patients with overt diabetes, bezafibrate reduces plasma glucose concentrations. 19,22 Recent studies have shown that type 2 diabetes is preventable by lifestyle interventions and by some medications that influence primary glucose metabolism. [23][24][25][26] Whether pharmacological interventions that influence primary lipid metabolism can also delay or prevent development of type 2 diabetes is unknown.…”

mentioning

confidence: 99%

Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease

et al. 2004

View full text Add to dashboard Cite

Background-Recent studies have shown that type 2 diabetes is preventable by both lifestyle interventions and medications that influence primary glucose metabolism. Whether pharmacological interventions that influence primary lipid metabolism can also delay development of type 2 diabetes is unknown. The goal of this study was to evaluate the effect of the peroxisome proliferator-activated receptor ligand bezafibrate on the progression of impaired fasting glucose phase to type 2 diabetes in patients with coronary artery disease over a 6.2-year follow-up period. Methods and Results-The study sample comprised 303 nondiabetic patients 42 to 74 years of age with a fasting blood glucose level of 110 to 125 mg/dL (6.1 to 6.9 mmol/L).

show abstract

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

Cited by 13 publications

References 23 publications

Prevention of type 2 diabetes: An update

Prevention of type 2 diabetes: An update

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease

Contact Info

Product

Resources

About